Goodman Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Goodman Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$139K	Sell	311 -68	-18%	-$31.7K	0.04%	88
2025 Q4	$172K	Hold	379	–	–	0.04%	74
2025 Q3	$148K	Sell	379 -21	-5%	-$8.78K	0.04%	78
2025 Q2	$178K	Sell	400 -44	-10%	-$20.3K	0.06%	59
2025 Q1	$215K	Buy	+444	New	+$207K	0.07%	75
2024 Q4	–	Sell	-492	Closed	-$229K	–	180
2024 Q3	$229K	Hold	492	–	–	0.07%	80
2024 Q2	$231K	Sell	492 -7	-1%	-$3.04K	0.07%	79
2024 Q1	$209K	Buy	499 +7	+1%	+$2.96K	0.07%	69
2023 Q4	$200K	Hold	492	–	–	0.07%	67
2023 Q3	$171K	Sell	492 -29	-6%	-$10.1K	0.06%	70
2023 Q2	$183K	Hold	521	–	–	0.07%	59
2023 Q1	$164K	Sell	521 -274	-34%	-$82.2K	0.09%	52
2022 Q4	$230K	Buy	795 +274	+53%	+$83.5K	0.13%	43
2022 Q3	$151K	Hold	521	–	–	0.08%	53
2022 Q2	$147K	Buy	+521	New	+$139K	0.07%	55

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Goodman Advisory Group's VRTX Position: Q1 2026 in Review

Goodman Advisory Group reduced its Vertex Pharmaceuticals (VRTX) stake by 18% in Q1 2026, selling an estimated $31.7K and leaving 311 shares worth $139K. The position accounts for 0.04% of the portfolio, ranked #88.

Goodman Advisory Group first reported a position in VRTX in Q2 2022 and has held it in 15 quarters since. The position peaked at $231K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Goodman Advisory Group held 311 shares of Vertex Pharmaceuticals worth $139K as of Q1 2026.
Goodman Advisory Group sold 68 Vertex Pharmaceuticals shares in Q1 2026, an estimated $31.7K.
Vertex Pharmaceuticals made up 0.04% of Goodman Advisory Group's portfolio in Q1 2026, its #88 holding.
Goodman Advisory Group first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 15 quarters since.
Goodman Advisory Group's Vertex Pharmaceuticals position peaked at $231K in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Goodman Advisory Group's 13F filing for Q1 2026, filed 22 Apr 2026.